{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:10:25Z","timestamp":1794085825085,"version":"4.8.0"},"reference-count":51,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate cancer (PC) has long been considered a disease of older men. Still, a significant and concerning rise in diagnoses among younger men has revealed a biologically distinct and more aggressive clinical entity: early-onset prostate cancer (EO-PC). This comprehensive review synthesizes the molecular and clinical evidence to demonstrate that PC is not a single disease, but a collection of distinct entities delineated by patient age. EO-PC is characterized by a strong genetic component, unique fusion events like TMPRSS2-ERG, and a highly plastic phenotype driven by intense Notch signaling and a hybrid epithelial-to-mesenchymal transition. In stark contrast, late-onset prostate cancer (LO-PC) is defined by a higher mutational burden, an epigenetic \u201cfield defect\u201d that accumulates with age, and a predominantly immunosuppressive tumor microenvironment. These profound biological differences have significant implications for diagnosis, prognosis, and therapeutic strategies. Traditional prognostic tools, such as the Gleason score, are often insufficient to capture the full spectrum of risk in younger men. The divergent molecular landscapes of EO-PC and LO-PC necessitate a fundamental shift from a standard approach to an age-aware precision medicine framework. This review highlights key therapeutic targets and underscores the critical need for a new paradigm in PC management to improve patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms26199777","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:22:08Z","timestamp":1759911728000},"page":"9777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular Landscape of Prostate Cancer Across Age Groups: Impact on Prognosis and Treatment Outcomes"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-8059","authenticated-orcid":false,"given":"Magdalena Julita","family":"Orzechowska","sequence":"first","affiliation":[{"name":"Department of Molecular Carcinogenesis, Medical University of \u0141\u00f3d\u017a, 90-752 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-4154","authenticated-orcid":false,"given":"Andrzej K.","family":"Bednarek","sequence":"additional","affiliation":[{"name":"Department of Molecular Carcinogenesis, Medical University of \u0141\u00f3d\u017a, 90-752 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-020-06083-6","article-title":"Global, regional, national burden of breast cancer in 185 countries: Evidence from GLOBOCAN 2018","volume":"187","author":"Sharma","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Liu, X., and Jiang, H. (2025). The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1553747"},{"key":"ref_3","first-page":"146","article-title":"The impact of socioeconomic status on the survival of men with early-onset prostate cancer","volume":"11","author":"Riveros","year":"2023","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12967-024-05190-y","article-title":"An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: Population-based cohort study","volume":"22","author":"Cheng","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cncr.32498","article-title":"Prostate cancer in young men: An emerging young adult and older adolescent challenge","volume":"126","author":"Bleyer","year":"2020","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/pros.24087","article-title":"Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality","volume":"81","author":"Shih","year":"2021","journal-title":"Prostate"},{"key":"ref_7","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Blasco","year":"2013","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/jmg-2024-109845","article-title":"Genetics of prostate cancer: A review of latest evidence","volume":"61","author":"Hall","year":"2024","journal-title":"J. Med. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lin, E., Garmo, H., Beckmann, K., Bratt, O., Akre, O., Stattin, P., and Gedeborg, R. (Int. J. Cancer, 2025). Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons, Int. J. Cancer, early view.","DOI":"10.1002\/ijc.70133"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrurol.2014.91","article-title":"Prostate cancer in young men: An important clinical entity","volume":"11","author":"Salinas","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.18231\/j.ijmpo.2022.011","article-title":"Prostate cancer in a 16-year old\u2014Is there a new shift?","volume":"8","author":"Haritha","year":"2022","journal-title":"IJMPO"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.seminoncol.2016.08.001","article-title":"Familial prostate cancer","volume":"43","author":"Giri","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.3390\/ijms140610822","article-title":"The genomic landscape of prostate cancer","volume":"14","author":"Spans","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ccell.2018.10.016","article-title":"Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories","volume":"34","author":"Gerhauser","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1200\/JCO.2023.41.16_suppl.5059","article-title":"Characterizing the molecular landscape of early onset and average onset prostate cancer","volume":"41","author":"Ogobuiro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2019). Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines, 6.","DOI":"10.3390\/medicines6030082"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pellestor, F., Ganne, B., Gaillard, J.B., and Gatinois, V. (2025). Chromoplexy: A Pathway to Genomic Complexity and Cancer Development. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083826"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated Evolution of Prostate Cancer Genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ccr.2013.04.025","article-title":"Chromoplexy: A new category of complex rearrangements in the cancer genome","volume":"23","author":"Shen","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_22","unstructured":"Esent\u00fcrk, E., Sahli, A., Haberland, V., Ziuboniewicz, A., Wirth, C., Bova, G.S., Bristow, R.G., Brook, M.N., Brors, B., and Butler, A. (2025). Causes of evolutionary divergence in prostate cancer. arXiv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100511","DOI":"10.1016\/j.xgen.2024.100511","article-title":"Genomic evolution shapes prostate cancer disease type","volume":"4","author":"Woodcock","year":"2024","journal-title":"Cell Genom."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.trecan.2022.06.007","article-title":"Age-associated differences in the cancer molecular landscape","volume":"8","author":"Chatsirisupachai","year":"2022","journal-title":"Trends Cancer."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2400841","DOI":"10.1200\/PO-24-00841","article-title":"Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy \u00b1 CDK4\/6 Inhibitors in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Systematic Review and Meta-Analysis","volume":"9","author":"Azim","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17352\/iec.000001","article-title":"Distinct genetic variants of early and late-onset prostate cancer","volume":"1","author":"Victor","year":"2023","journal-title":"Insights Epigenet. Chromatin"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: An emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature22820","article-title":"ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis","volume":"546","author":"Bose","year":"2017","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/pros.22716","article-title":"Epigenetic susceptibility factors for prostate cancer with aging","volume":"73","author":"Damaschke","year":"2013","journal-title":"Prostate"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.21037\/tau-20-1339","article-title":"Epigenetics in prostate cancer: Clinical implications","volume":"10","author":"Conteduca","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2004.06.014","article-title":"Molecular detection of prostate cancer: A role for GSTP1 hypermethylation","volume":"46","author":"Henrique","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/jco.2015.33.7_suppl.20","article-title":"Epigenetic field effects: Potential applications for detection of occult high-grade prostate cancer","volume":"33","author":"Gaston","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.21037\/tau-24-382","article-title":"DNA methylation alterations in prostate cancer: From diagnosis to treatment","volume":"14","author":"Barletta","year":"2025","journal-title":"Transl. Androl. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jedroszka, D., Orzechowska, M., Hamouz, R., Gorniak, K., and Bednarek, A.K. (2017). Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188842"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Orzechowska, M.J., Anusewicz, D., and Bednarek, A.K. (2022). Age- and Stage-Dependent Prostate Cancer Aggressiveness Associated with Differential Notch Signaling. Int. J. Mech. Sci., 24.","DOI":"10.3390\/ijms24010164"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chen, P., Li, B., and Ou-Yang, L. (2022). Role of estrogen receptors in health and disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.839005"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, Y., Chen, Y., and Wang, J. (2025). Role of Tumor Microenvironment in Prostate Cancer Immunometabolism. Biomolecules, 15.","DOI":"10.3390\/biom15060826"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12964-025-02082-6","article-title":"Immunosenescence promotes cancer development: From mechanisms to treatment strategies","volume":"23","author":"Wang","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Shakeri Abroudi, A., Mashhouri Moghaddam, M., Hashemi Karoii, D., Djamali, M., Azizi, H., and Skutella, T. (2025). Analysis of Microarray and Single-Cell RNA-Seq Finds Gene Co-Expression and Tumor Environment Associated with Extracellular Matrix in Epithelial\u2013Mesenchymal Transition in Prostate Cancer. Int. J. Mech. Sci., 26.","DOI":"10.3390\/ijms26178575"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"478126","DOI":"10.1155\/2014\/478126","article-title":"Senescent Remodeling of the Innate and Adaptive Immune System in the Elderly Men with Prostate Cancer","volume":"2014","author":"Taverna","year":"2014","journal-title":"Curr. Gerontol. Geriatr. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ding, Y., Wu, H., Warden, C., Steele, L., Liu, X., van Iterson, M., Wu, X., Nelson, R., Liu, Z., and Yuan, Y.-C. (2016). Gene Expression Differences in Prostate Cancers between Young and Old Men. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1006477"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.7150\/ijbs.87334","article-title":"The critical role of \u03b3-secretase and its inhibitors in cancer and cancer therapeutics","volume":"19","author":"Song","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"29906","DOI":"10.18632\/oncotarget.25692","article-title":"A mechanism-based computational model to capture the interconnections among epithelial-mesenchymal transition, cancer stem cells and Notch-Jagged signaling","volume":"9","author":"Bocci","year":"2018","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E402","DOI":"10.1073\/pnas.1416287112","article-title":"Jagged-Delta asymmetry in Notch signaling can give rise to a Sender\/Receiver hybrid phenotype","volume":"112","author":"Boareto","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"pkad052","DOI":"10.1093\/jncics\/pkad052","article-title":"Use of the Decipher genomic classifier among men with prostate cancer in the United States","volume":"7","author":"Zaorsky","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kwon, W.A., and Joung, J.Y. (2025). Immunotherapy in Prostate Cancer: From a \u201cCold\u201d Tumor to a \u201cHot\u201d Prospect. Cancers, 17.","DOI":"10.3390\/cancers17071064"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1002\/onco.13627","article-title":"Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance","volume":"26","author":"McCaw","year":"2021","journal-title":"Oncologist"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Di Zazzo, E., Galasso, G., Giovannelli, P., Di Donato, M., and Castoria, G. (2018). Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00002"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Di Zazzo, E., Galasso, G., Giovannelli, P., Di Donato, M., Bilancio, A., Perillo, B., Sinisi, A.A., Migliaccio, A., and Castoria, G. (2019). Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate Cancer. Cancers, 11.","DOI":"10.3390\/cancers11101418"},{"key":"ref_50","first-page":"718","article-title":"Notch and epithelial-mesenchyme transition in development and tumor progression: Another turn of the screw","volume":"3","author":"Diez","year":"2004","journal-title":"Cell Cycle"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Olczak, M., Orzechowska, M.J., Bednarek, A.K., and Lipi\u0144ski, M. (2023). The Transcriptomic Profiles of ESR1 and MMP3 Stratify the Risk of Biochemical Recurrence in Primary Prostate Cancer beyond Clinical Features. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098399"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:16Z","timestamp":1760035816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":51,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199777"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199777","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}